Objectives: To investigate the dynamics of HIV-1 variants archived in cells harbouring drug resistance-associated mutations (DRAMs) to lamivudine/emtricitabine, etravirine and rilpivirine in patients under effective ART free from selective pressure on these DRAMs, in order to assess the possibility of recycling molecules with resistance history.
Introduction
In view of the prolongation of life expectancy for patients living with HIV, the question of optimization of ART, which is still a lifelong treatment, becomes central. 1, 2 Although most patients achieve virological success, their treatments often need to be optimized to limit adverse events and drug interactions and improve adherence.
Circulating HIV-1 resistant variants can be archived in viral reservoirs, where they can persist for an unknown duration and re-emerge in the presence of therapeutic selective pressure. 3, 4 Residual viraemia (HIV viral load ,50 copies/mL) under effective ART has been found in 60% to 80% of patients in several studies. 5 It leads to persistent evolution of the diversity of archived viral quasispecies in PBMCs. 6, 7 The main objective of this study was to investigate, by ultra-deep sequencing (UDS), the dynamics of decay and the persistence of DNA HIV-1 variants harbouring drug resistance-associated mutations (DRAMs) to key molecules of the antiretroviral strategy, namely lamivudine/emtricitabine, etravirine and rilpivirine, in patients with sustained virological control for at least 5 years under effective ART free from therapeutic selective pressure on these DRAMs.
Patients and methods

Study population
In 2016, we retrospectively selected 25 patients followed up in the Departments of Infectious Diseases and Internal Medicine in Pitié-Salpêtrière Hospital (Paris, France) infected with HIV-1 B subtype, treated in the past with NRTI and/or NNRTI with selection of at least one DRAM to lamivudine/emtricitabine (n " 13 for the NRTI-off group, patients 15 to 25) and/or etravirine and/or rilpivirine (n " 14 for the NNRTI-off group, patients 1 to 14), identified V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
on an RNA sequence in their history (between 2000 and 2010), and with viral suppression (HIV plasma RNA ,50 copies/mL) for at least 5 years under a therapeutic regimen excluding all drugs of the resistant class (all NRTI and/or all NNRTI). Two patients met the inclusion criteria of both groups (patients 9 and 11). Analyses were performed retrospectively on frozen samples of whole blood taken during the 5 years of follow-up.
Ethics
All the patients gave their written informed consent to have their medical chart recorded in the electronic medical record system Nadis V R (www.dataids.org; Fedialis Medica, Marly Le Roi, France; CNIL number: 770134, 30 October 2001).
Total HIV-DNA quantification
Cell-associated HIV-1 DNA was quantified by ultrasensitive real-time PCR as previously described. 8 Reverse transcriptase genotypic drug resistance testing by Sanger sequencing and UDS Sanger sequencing and UDS were performed according to the Agence Nationale de recherche sur le SIDA et les hépatites virales (ANRS) consensus and using Illumina technology (Illumina, San Diego, CA, USA), respectively, as previously described. 9 The sequence reads were analysed with IDNS V R software v3_8_0r4 ( V C SmartGene), and resistance was interpreted using the latest ANRS resistance algorithm (http://www.hivfrenchresistance.org). 9 For UDS, the minimum coverage was set at 50 and the ambiguity filter at 1%.
Identification of defective and hypermutated G-to-A viruses
G-to-A mutation frequencies were analysed using the Hypermut 2.0 program (www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html) in DNA sequences obtained from Sanger sequencing.
Ultrasensitive plasma HIV-1 RNA quantification
Plasma HIV-1 RNA viral load was quantified by a real-time PCR assay using the COBASV R Ampliprep/COBASV R TaqManV R HIV-1 test, V2.0 (Roche). Below the standard cut-off, the assay indicates the presence/absence of HIV-1 RNA.
Results
Patients' characteristics at baseline in 2011
Patients' characteristics at baseline are described in Table 1 . ART is described in Figure 1 . Treatment  41L  44D  67N  69D  70R  74V 184V 210W 215Y 215F 219Q 219E  11 Drug resistance-associated mutations in HIV-1 JAC (patient 25) or emergence of new DRAMs (patients 18, 22, 24 and 25) (Figure 1a ). In the NNRTI-off group, 11/14 patients had NNRTI DRAMs detectable in their HIV-1 DNA sequence at baseline (patients 1, 9 and 14 had no DRAMs detectable, not shown), of whom 8 showed progressive clearance of these DRAMs (Figure 1b ) and 3 showed persistence (patient 4) or emergence (patients 6 and 7) of some DRAMs (Figure 1b) .
Overall, the analysed DRAMs were no longer detected after 5 years in 18/25 patients (72%), and interpretation with the ANRS resistance algorithm found viruses susceptible to the molecules of interest in 20/25 patients (80%) at 5 years (2/5 patients who still had NRTI DRAMs had viruses susceptible to lamivudine/ emtricitabine).
Characteristics (age, sex, duration of infection and treatment, viral load zenith, CD4! cell count nadir, total cell HIV-1 DNA level, Treatment  90I  98G 100I 101E 103N 103R 106I 138A 138G 138K 179I 181C 188L 190A 221Y 225H  2  RNA  +  +  +  DNA 2011  TDF FTC DRV/r  100  0  0  2016  TDF FTC DTG  0  0  0 
Comparison of Sanger sequencing and UDS results
In 11/67 (16%) sequencing results, some DRAMs detected by UDS and not by Sanger sequencing, with frequencies between 1.1% and 21.3%, led to a different interpretation of resistance by the ANRS algorithm. Thus, Sanger sequencing found viruses interpreted as susceptible to the molecules of interest in 22/25 patients (88%) at 5 years. Notably, some DRAMs detected by UDS and not by Sanger had frequencies higher than 20%, up to 40.7%.
Residual viraemia
Residual viraemia was found at least once during the 5 years in 13 patients (52%), of whom 9 showed progressive clearance of archived DRAMs (patients 1, 3, 8, 10, 11, 12, 13, 15 and 23), and 4 showed persistence or (re-)emergence of archived DRAMs (patients 6, 7, 17 and 27).
Cell-associated HIV-1 DNA quantification
The median total cell-associated HIV-1 DNA load remained stable (2.4 log 10 copies/10 6 cells at baseline versus 2.1 log 10 copies/10 6 cells at 5 years). The total cell-associated HIV-1 DNA load was not detectable (,66 copies/10 6 cells) in 13 samples.
APOBEC3-induced G-to-A mutations and defective viruses
Two patients had statistically significant (P , 0.05) G-to-A mutation frequencies in their HIV-1 DNA Sanger sequences: patient 20 with 35 G-to-A mutations in 2011 and patient 23 with 3, 3 and 27 G-to-A mutations in 2013, 2014 and 2016 respectively. Thirteen patients (52%) had stop codons and/or G-to-A DRAMs (184I and 230I) in their UDS sequence reads, with frequencies between 2.3% and 100%. These frequencies increased over time in 69% of them. Sanger sequencing detected fewer stop codons and G-to-A mutations than UDS, with frequencies up to 37.5%.
Discussion
These results show a clear trend towards progressive clearance over time of archived DRAMs to reverse transcriptase inhibitors in cell-associated HIV-1 DNA in these 25 patients with suppressed plasma viral load under a therapeutic regimen free from crossselective pressure on these DRAMs.
This dynamic is probably due mainly to preferential residual replication in some reservoirs of the fittest viruses among the quasispecies and the removal of the therapeutic pressure of an entire drug class. These viruses might be released into the blood from reservoirs, leading to persistent residual viraemia under treatment and replenishment of peripheral reservoirs with these viruses free of DRAMs, with clearance of resistant proviruses.
6,7,10 However, some DRAMs to the removed therapeutic class could be linked on the same viral variant to other DRAMs conferring resistance to the current regimen, and could therefore be indirectly selected by the therapeutic pressure, 7 thus explaining the emergence of some DRAMs. Indeed, DRAMs can emerge even in the case of minimal viral replication, with a suppressed plasma viral load (,50 copies/mL). 3, 11 The dynamics of DRAMs archived in HIV-1 DNA did not seem to be correlated to the HIV-1 DNA level in the cell reservoir, as these levels did not vary over the 5 years of follow-up. This 5 year period is indeed probably too short to find a significant decrease in HIV-1 DNA level, especially for patients whose treatment was initiated in the chronic phase of infection. 12 This study has several limitations. The number of included patients was low, probably because of strict inclusion criteria and the study's monocentric nature. The low HIV-1 DNA viral load could induce in UDS many reads of a few genomes, in which case evolution of mutations becomes stochastic rather than biological events. The absence of variations in the HIV-1 DNA viral load and the longitudinal aspect of the study are not in favour of this hypothesis. Furthermore, an analysis of DRAM dynamics in anatomical reservoirs could be interesting, as viral genetic diversity and mutational resistance patterns can vary in some body compartments. 3 In conclusion, these results show a clear trend towards progressive clearance of archived DRAMs to reverse transcriptase inhibitors in cell-associated HIV-1 DNA after a long period of virological control free of therapeutic selective pressure on those DRAMs. These results provide a rationale for further clinical evaluation of drug recycling in selected patients with sustained virological control under non-optimal regimens, after genotypic resistance testing by UDS in archived HIV-1 DNA.
